Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial
NCT ID: NCT01152060
Last Updated: 2010-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2010-01-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Optimizing Research of Lamivudine Therapy
NCT01088009
Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
NCT00338780
Biomarkers Guided Stopping NAs Treatment
NCT04519359
Antiviral Therapy in Infants With HBV Infection
NCT06503796
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
NCT01487876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
prednisone
No interventions assigned to this group
prednisone and anti-virus
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanchang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
second affiliated hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gaosi XU, MD & PhD
Role: STUDY_DIRECTOR
second affiliated hospital to nanchang university
References
Explore related publications, articles, or registry entries linked to this study.
von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, Tunnicliffe DJ. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.
Xu G, Duang Z, Wu X, Zou H, Fang X, Tu W. Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial. Clin Chem Lab Med. 2011 Jun;49(6):1077-8. doi: 10.1515/CCLM.2011.168. Epub 2011 Mar 17. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT00100504
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.